RxDoctor Payments Data

Mohamed Gashouta, MD

Critical Care Medicine · Galesburg, ILNPI 1427311877

Payments from drug & device makers

$151in general payments, 2019–2025

Across 11 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$36
  • Sunovion Pharmaceuticals Inc.$28
  • Boehringer Ingelheim$25
  • Johnson & Johnson$17
  • Novartis$16
  • Insmed, Inc.$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$151 in reported general payments places this provider in the 30th percentile of 281 critical care medicine providers in Illinois.

See all critical care medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$136,559
Medicare patients
810
Services billed
2,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter235$178,971
Dupixent PenDupilumab15$65,696
Stiolto RespimatTiotropium Br/Olodaterol Hcl94$55,281
Breztri AerosphereBudesonide/Glycopyr/Formoterol86$52,889
Incruse ElliptaUmeclidinium Bromide137$49,725
NucalaMepolizumab13$48,358
Breo ElliptaFluticasone/Vilanterol105$45,729
Spiriva RespimatTiotropium Bromide66$38,646
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr61$34,052
SymbicortBudesonide/Formoterol Fumarate75$18,429
Arnuity ElliptaFluticasone Furoate57$13,156
Bevespi AerosphereGlycopyrrolate/Formoterol Fum21$11,436
Albuterol Sulfate HfaAlbuterol Sulfate225$6,453
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate32$5,079
Advair HfaFluticasone Propion/Salmeterol12$4,434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Incruse Ellipta, Nucala, Breo Ellipta, Anoro Ellipta$14$369,991608 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$25$93,927160 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$36$82,754182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 281 critical care medicine providers in Illinois.

Other critical care medicine in Galesburg

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →